|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
CN102625832A
(zh)
|
2009-08-24 |
2012-08-01 |
贝勒医学院 |
产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
|
|
EP2569633B1
(en)
*
|
2010-05-14 |
2016-02-10 |
The General Hospital Corporation |
Compositions and methods of identifying tumor specific neoantigens
|
|
HRP20250981T1
(hr)
*
|
2011-05-24 |
2025-10-24 |
BioNTech SE |
Individualizirana cjepiva protiv raka
|
|
HRP20191535T1
(hr)
*
|
2011-05-24 |
2019-11-29 |
Biontech Rna Pharmaceuticals Gmbh |
Individualizirana cjepiva protiv raka
|
|
US20140303020A1
(en)
*
|
2011-08-02 |
2014-10-09 |
The University Of Tokyo |
Method for Assessing Myelodysplastic Syndrome or Myeloid Tumor Predisposition, Polypeptide and Antibody Therefor, and Candidate Screening Method for Therapeutic Drug or Prophylactic Drug Therefor
|
|
JP2014530013A
(ja)
*
|
2011-09-29 |
2014-11-17 |
トローバジーン インコーポレイテッド |
Ｓｆ３ｂ１遺伝子における変異および慢性リンパ性白血病
|
|
US20140364439A1
(en)
*
|
2011-12-07 |
2014-12-11 |
The Broad Institute, Inc. |
Markers associated with chronic lymphocytic leukemia prognosis and progression
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
DK2812431T3
(da)
|
2012-02-09 |
2019-10-14 |
Baylor College Medicine |
Peptidblandinger til generering af multivirale ctl'er med bred specificitet
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
EP2854842A4
(en)
|
2012-05-25 |
2016-11-02 |
Agenus Inc |
IDENTIFICATION OF MHC CLASS I PHOSPHOPEPTIDE ANTIGENES FROM BREAST CANCER BY SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES
|
|
EP3511425A1
(en)
*
|
2012-07-12 |
2019-07-17 |
Persimmune, Inc. |
Personalized cancer vaccines and adoptive immune cell therapies
|
|
GB201214007D0
(en)
*
|
2012-08-07 |
2012-09-19 |
Scancell Ltd |
Anti-tumour immune responses to modified self-epitopes
|
|
HK1212237A1
(en)
|
2012-08-31 |
2016-06-10 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
EP2892544A4
(en)
|
2012-09-05 |
2016-11-02 |
Univ Virginia Patent Found |
TARGET PEPTIDES FOR THERAPY AND DIAGNOSIS OF COLORECTAL CARCINOMAS
|
|
DK2901341T3
(da)
|
2012-09-28 |
2019-07-15 |
Univ Connecticut |
Identifikation af tumorbeskyttelsesepitoper til behandling af cancere
|
|
EP2925348B1
(en)
|
2012-11-28 |
2019-03-06 |
BioNTech RNA Pharmaceuticals GmbH |
Individualized vaccines for cancer
|
|
GB2508414A
(en)
*
|
2012-11-30 |
2014-06-04 |
Max Delbrueck Centrum |
Tumour specific T cell receptors (TCRs)
|
|
EP3578200A1
(en)
|
2013-02-22 |
2019-12-11 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
CN105073135A
(zh)
|
2013-02-22 |
2015-11-18 |
库瑞瓦格有限责任公司 |
疫苗接种和抑制pd-1途径的组合
|
|
US10435668B2
(en)
|
2013-03-14 |
2019-10-08 |
The Johns Hopkins University |
Nanoscale artificial antigen presenting cells
|
|
AU2014251207B2
(en)
*
|
2013-04-07 |
2019-06-13 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for personalized neoplasia vaccines
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
CN106132432A
(zh)
*
|
2013-12-06 |
2016-11-16 |
博德研究所 |
用于瘤形成疫苗的配制品
|
|
JP7060324B2
(ja)
*
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ネオ抗原ワクチンによる併用療法
|
|
EP3090066A4
(en)
*
|
2014-01-02 |
2017-08-30 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
|
WO2015160928A2
(en)
|
2014-04-15 |
2015-10-22 |
University Of Virginia Patent Foundation |
Isolated t cell receptors and methods of use therefor
|
|
JP7044551B2
(ja)
*
|
2014-09-10 |
2022-03-30 |
ジェネンテック， インコーポレイテッド |
免疫原性変異体ペプチドスクリーニングプラットフォーム
|
|
US11338026B2
(en)
|
2014-09-10 |
2022-05-24 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
AU2015315559A1
(en)
*
|
2014-09-10 |
2017-02-16 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
AU2015314776A1
(en)
*
|
2014-09-14 |
2017-04-06 |
Washington University |
Personalized cancer vaccines and methods therefor
|
|
MX383271B
(es)
|
2014-09-17 |
2025-03-13 |
Univ Johns Hopkins |
Reactivos y metodos para identificar, enriquecer y/o expandir celulas t especificas de antigeno.
|
|
PT3193917T
(pt)
*
|
2014-09-17 |
2021-10-20 |
Io Biotech Aps |
Composições de vacina compreendendo triptofano-2,3-dioxigenase ou fragmentos desta
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
CA2963364A1
(en)
|
2014-10-02 |
2016-04-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
|
|
US20160101128A1
(en)
*
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
|
MA40737A
(fr)
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
EP4636401A2
(en)
|
2014-12-19 |
2025-10-22 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
EP4537906A3
(en)
*
|
2015-03-25 |
2025-08-20 |
The Regents of the University of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US20190099475A1
(en)
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
JP7236216B2
(ja)
|
2015-04-23 |
2023-03-09 |
ナントミクス，エルエルシー |
がんのネオエピトープ
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
HUE052106T2
(hu)
*
|
2015-04-27 |
2021-04-28 |
Cancer Research Tech Ltd |
Eljárás rák kezelésére
|
|
AU2016258845B2
(en)
|
2015-05-01 |
2022-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
EP3294324A1
(en)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
MX2017014700A
(es)
*
|
2015-05-20 |
2018-08-15 |
Broad Inst Inc |
Neoantigenos compartidos.
|
|
TW202241500A
(zh)
*
|
2015-06-09 |
2022-11-01 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
CA3255210A1
(en)
|
2015-07-14 |
2025-03-19 |
Personal Genome Diagnostics Inc. |
Neoantigen analysis
|
|
EP3328394A4
(en)
*
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
CONCATEMEE peptide epitope RNAs
|
|
GB201516047D0
(en)
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
CA2998649A1
(en)
*
|
2015-09-18 |
2017-03-23 |
Baylor College Of Medicine |
Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
EP3362929B1
(en)
*
|
2015-10-12 |
2020-08-12 |
Nantomics, LLC |
Viral neoepitopes and uses thereof
|
|
JP2018532736A
(ja)
|
2015-10-12 |
2018-11-08 |
ナントミクス，エルエルシー |
チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法
|
|
JP2018535202A
(ja)
|
2015-10-12 |
2018-11-29 |
ナントミクス，エルエルシー |
ネオエピトープの反復発見と適応可能な免疫療法およびその方法
|
|
KR20180083327A
(ko)
|
2015-10-12 |
2018-07-20 |
난토믹스, 엘엘씨 |
바이러스성 암 네오에피토프를 위한 조성물 및 방법
|
|
CA3003090A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Cancer vaccines
|
|
RU2743169C2
(ru)
|
2015-11-06 |
2021-02-15 |
Вентана Медикал Системз, Инк. |
Репрезентативная диагностика
|
|
TWI733719B
(zh)
*
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
US20170199961A1
(en)
|
2015-12-16 |
2017-07-13 |
Gritstone Oncology, Inc. |
Neoantigen Identification, Manufacture, and Use
|
|
WO2017112954A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Moonshot Pharma Llc |
Methods for inducing an immune response by promoting premature termination codon read-through
|
|
AU2017205270B2
(en)
|
2016-01-08 |
2024-01-18 |
Nykode Therapeutics ASA |
Therapeutic anticancer neoepitope vaccine
|
|
US20170224796A1
(en)
|
2016-02-05 |
2017-08-10 |
Xeme Biopharma Inc. |
Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
|
|
EP3414692A4
(en)
*
|
2016-02-12 |
2020-07-29 |
Nantomics, LLC |
HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES
|
|
CN105720176A
(zh)
*
|
2016-02-19 |
2016-06-29 |
京东方科技集团股份有限公司 |
一种胶囊量子点和发光二极管、制备方法及显示装置
|
|
KR20180107257A
(ko)
|
2016-02-19 |
2018-10-01 |
난트 홀딩스 아이피, 엘엘씨 |
면역원 조절 방법 (methods of immunogenic modulation)
|
|
SG11201807770RA
(en)
*
|
2016-03-24 |
2018-10-30 |
Nantcell Inc |
Sequence arrangements and sequences for neoepitope presentation
|
|
WO2017177207A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Bostongene, Llc |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
US20190062272A1
(en)
*
|
2016-04-13 |
2019-02-28 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
EP3471778A4
(en)
|
2016-06-20 |
2020-02-19 |
The Regents of The University of Michigan |
COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS
|
|
US20190247435A1
(en)
*
|
2016-06-29 |
2019-08-15 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
JP2019522486A
(ja)
|
2016-07-13 |
2019-08-15 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
抗原提示細胞模倣足場およびそれを作製および使用するための方法
|
|
AU2017299162B2
(en)
*
|
2016-07-20 |
2024-09-26 |
BioNTech SE |
Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
|
|
CN109906086A
(zh)
*
|
2016-08-02 |
2019-06-18 |
河谷细胞有限公司 |
树突细胞的转染及其方法
|
|
US20190237158A1
(en)
*
|
2016-08-31 |
2019-08-01 |
Medgenome, Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
JP7200093B2
(ja)
|
2016-09-15 |
2023-01-06 |
アイデラ・ファーマシューティカルズ，インコーポレーテッド |
がん治療用ｔｌｒ９アゴニストを用いた免疫調節
|
|
US11976299B2
(en)
|
2016-09-23 |
2024-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
US20190240257A1
(en)
*
|
2016-10-13 |
2019-08-08 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
EP4338799A3
(en)
*
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
WO2018089637A1
(en)
|
2016-11-11 |
2018-05-17 |
Nantbio, Inc. |
Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
|
|
WO2018102613A2
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
WO2018144775A1
(en)
*
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
AU2017397458B2
(en)
*
|
2017-02-01 |
2025-07-10 |
Modernatx, Inc. |
RNA cancer vaccines
|
|
AU2018240199A1
(en)
*
|
2017-03-20 |
2019-10-17 |
Genocea Biosciences, Inc. |
Treatment methods
|
|
WO2018183544A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Method for identification of retained intron tumor neoantigens from patient transcriptome
|
|
CN118370809A
(zh)
|
2017-04-03 |
2024-07-23 |
百欧恩泰美国公司 |
蛋白质抗原及其用途
|
|
WO2018187515A1
(en)
|
2017-04-04 |
2018-10-11 |
Avidea Technologies, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
|
US20210113673A1
(en)
*
|
2017-04-19 |
2021-04-22 |
Gritstone Oncology, Inc. |
Neoantigen Identification, Manufacture, and Use
|
|
JP7051898B2
(ja)
|
2017-04-24 |
2022-04-11 |
ナントセル，インコーポレイテッド |
標的型ネオエピトープベクター及びそのための方法
|
|
MX2019013259A
(es)
|
2017-05-08 |
2020-01-13 |
Gritstone Oncology Inc |
Vectores de neoantigeno de alfavirus.
|
|
WO2018209145A1
(en)
|
2017-05-10 |
2018-11-15 |
The Broad Institute, Inc. |
Methods and compositions for determination of mutations in single replication events
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
CN110996970A
(zh)
*
|
2017-06-02 |
2020-04-10 |
亚利桑那州立大学董事会 |
创建个性化癌症疫苗的方法
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
KR102684237B1
(ko)
*
|
2017-06-21 |
2024-07-11 |
트랜스진 |
개인 맞춤형 백신
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
CN118846017A
(zh)
|
2017-07-21 |
2024-10-29 |
伯克利之光生命科技公司 |
抗原呈递合成表面、共价官能化表面、活化t细胞及其用途
|
|
EP3658683A4
(en)
|
2017-07-25 |
2021-04-21 |
California Institute of Technology |
TROGOCYTOSIS-MEDIATED EPITOPE DISCOVERY
|
|
WO2019036043A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Medgenome Inc. |
METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
|
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
|
|
CA3076918A1
(en)
*
|
2017-10-02 |
2019-04-11 |
Curematch, Inc. |
Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
|
|
AU2018345715A1
(en)
*
|
2017-10-06 |
2020-05-21 |
The Wistar Institute Of Anatomy And Biology |
DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
|
|
ES3029080T3
(en)
|
2017-10-10 |
2025-06-23 |
Seattle Project Corp |
Neoantigen identification using hotspots
|
|
AU2018361561C1
(en)
*
|
2017-11-06 |
2025-07-03 |
Ludwig Institute For Cancer Research Ltd |
Method for expansion of lymphocytes
|
|
US20210154277A1
(en)
*
|
2017-11-07 |
2021-05-27 |
Nektar Therapeutics |
Immunotherapeutic combination for treating cancer
|
|
EP3706784A4
(en)
|
2017-11-08 |
2021-12-01 |
BioNTech US Inc. |
COMPOSITIONS AND METHODS OF MANUFACTURING T-CELLS
|
|
US11885815B2
(en)
|
2017-11-22 |
2024-01-30 |
Gritstone Bio, Inc. |
Reducing junction epitope presentation for neoantigens
|
|
CN109682978B
(zh)
*
|
2017-11-30 |
2020-07-03 |
四川康德赛医疗科技有限公司 |
一种肿瘤突变肽mhc亲和力预测方法及其应用
|
|
WO2019126186A1
(en)
|
2017-12-18 |
2019-06-27 |
Neon Therapeutics, Inc. |
Neoantigens and uses thereof
|
|
EP4495597A3
(en)
|
2018-01-04 |
2025-04-30 |
Iconic Therapeutics LLC |
Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
|
|
EP3743102A1
(en)
|
2018-01-26 |
2020-12-02 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
US11573230B2
(en)
|
2018-01-26 |
2023-02-07 |
Nantcell, Inc. |
Rapid verification of virus particle production for a personalized vaccine
|
|
CN108491689B
(zh)
*
|
2018-02-01 |
2019-07-09 |
杭州纽安津生物科技有限公司 |
基于转录组的肿瘤新抗原鉴定方法
|
|
TW202000693A
(zh)
*
|
2018-02-27 |
2020-01-01 |
美商葛利史東腫瘤科技公司 |
利用泛對偶基因（pan-allele）模型之新抗原鑑別
|
|
US11065317B2
(en)
|
2018-04-26 |
2021-07-20 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
TW202000907A
(zh)
|
2018-05-23 |
2020-01-01 |
美商葛利史東腫瘤科技公司 |
共有抗原
|
|
CA3100974A1
(en)
*
|
2018-05-25 |
2020-11-28 |
The Wistar Institute |
Tumor-specific neoantigens and methods of using the same
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
EP3810182A4
(en)
|
2018-06-19 |
2022-08-24 |
BioNTech US Inc. |
Neoantigens and uses thereof
|
|
IL280113B2
(en)
|
2018-07-26 |
2025-11-01 |
Curevac Netherlands B V |
Cancer vaccines for uterine cancer
|
|
WO2020022900A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for kidney cancer
|
|
IL280112B2
(en)
|
2018-07-26 |
2025-11-01 |
Curevac Netherlands B V |
Cancer vaccines for breast cancer
|
|
EP3826669A2
(en)
|
2018-07-26 |
2021-06-02 |
Frame Pharmaceuticals B.V. |
Off-the-shelf cancer vaccines
|
|
US12005104B2
(en)
|
2018-07-26 |
2024-06-11 |
Curevac Netherlands B.V. |
Cancer vaccines for colorectal cancer
|
|
IL321691A
(en)
|
2018-07-26 |
2025-08-01 |
Curevac Netherlands B V |
arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines against cancer
|
|
CN109021062B
(zh)
*
|
2018-08-06 |
2021-08-20 |
倍而达药业（苏州）有限公司 |
一种肿瘤新抗原的筛选方法
|
|
CN121354685A
(zh)
|
2018-08-31 |
2026-01-16 |
夸登特健康公司 |
无细胞dna中的微卫星不稳定性检测
|
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
|
WO2020061499A1
(en)
|
2018-09-21 |
2020-03-26 |
Berkeley Lights, Inc. |
Functionalized well plate, methods of preparation and use thereof
|
|
CA3111903A1
(en)
|
2018-09-27 |
2020-04-02 |
Vaccibody As |
Method for selecting neoepitopes
|
|
AU2019362009A1
(en)
|
2018-10-18 |
2021-06-03 |
Berkeley Lights, Inc. |
Proto-antigen-presenting synthetic surfaces, activated t cells, and uses thereof
|
|
MX2021005372A
(es)
|
2018-11-08 |
2021-09-14 |
Neximmune Inc |
Composiciones de linfocitos t con propiedades fenotípicas mejoradas.
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109706065A
(zh)
*
|
2018-12-29 |
2019-05-03 |
深圳裕策生物科技有限公司 |
肿瘤新生抗原负荷检测装置及存储介质
|
|
US20200291355A1
(en)
|
2019-02-20 |
2020-09-17 |
Rubius Therapeutics, Inc. |
Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
|
|
CN111621564B
(zh)
*
|
2019-02-28 |
2022-03-25 |
武汉大学 |
一种鉴定有效肿瘤新抗原的方法
|
|
US12427195B1
(en)
*
|
2019-03-11 |
2025-09-30 |
La Jolla Institute For Immunology |
Methods of neoantigen identification
|
|
US20220130489A1
(en)
*
|
2019-03-12 |
2022-04-28 |
Syntekabio,Inc. |
System and method for providing neoantigen immunotherapy information by using artificial-intelligence-model-based molecular dynamics big data
|
|
EP3963335B1
(en)
*
|
2019-05-03 |
2024-08-21 |
Epivax Therapeutics, Inc. |
Neoantigens in cancer
|
|
US20220220472A1
(en)
*
|
2019-05-06 |
2022-07-14 |
The Regents Of The University Of Michigan |
Targeted therapy
|
|
JP7457733B2
(ja)
|
2019-05-30 |
2024-03-28 |
グリットストーン バイオ インコーポレイテッド |
改変アデノウイルス
|
|
CN112011833B
(zh)
*
|
2019-05-30 |
2024-04-26 |
上海桀蒙生物技术有限公司 |
筛选和分离肿瘤新生抗原的方法
|
|
CN110322925B
(zh)
*
|
2019-07-18 |
2021-09-03 |
杭州纽安津生物科技有限公司 |
一种预测融合基因产生新生抗原的方法
|
|
CN110706747B
(zh)
*
|
2019-09-17 |
2021-09-07 |
北京橡鑫生物科技有限公司 |
检测肿瘤新生抗原多肽的方法和装置
|
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
US11920202B2
(en)
|
2020-04-09 |
2024-03-05 |
University Of Connecticut |
Unbiased identification of tumor rejection mediating neoepitopes
|
|
WO2021230247A1
(ja)
*
|
2020-05-12 |
2021-11-18 |
大日本住友製薬株式会社 |
癌を処置するための医薬組成物
|
|
EP4149952A1
(en)
*
|
2020-05-12 |
2023-03-22 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
|
WO2021252904A1
(en)
|
2020-06-11 |
2021-12-16 |
Massachusetts Institute Of Technology |
Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
|
|
EP4192496A4
(en)
|
2020-08-06 |
2025-01-01 |
Gritstone bio, Inc. |
MULTIEPITOP VACCINE CASSETTES
|
|
US20230374455A1
(en)
|
2020-08-13 |
2023-11-23 |
Biontech Us Inc. |
T cell manufacturing compositions and methods
|
|
GB2613718A
(en)
*
|
2020-08-31 |
2023-06-14 |
World Biotech Regenerative Medical Group Ltd |
Personalized immunogenic compositions and methods for producing and using same
|
|
KR102552632B1
(ko)
*
|
2020-11-06 |
2023-07-06 |
사회복지법인 삼성생명공익재단 |
중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
|
|
CA3212877A1
(en)
*
|
2021-03-26 |
2022-09-29 |
Sunil Sharma |
Methods and compounds for neoantigen vaccines
|
|
CN117321189A
(zh)
|
2021-04-30 |
2023-12-29 |
泰根制药有限公司 |
淋巴细胞的单血管扩增
|
|
EP4346884A1
(en)
*
|
2021-05-27 |
2024-04-10 |
Amazon Technologies, Inc. |
Multicomponent chemical composition of a peptide-based neoantigen vaccine
|
|
AU2021461416A1
(en)
|
2021-08-24 |
2024-02-22 |
BioNTech SE |
In vitro transcription technologies
|
|
CN115772564B
(zh)
*
|
2021-09-08 |
2023-08-18 |
广州市基准医疗有限责任公司 |
用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
|
|
EP4419716A1
(en)
|
2021-10-21 |
2024-08-28 |
CureVac Netherlands B.V. |
Cancer neoantigens
|
|
CN116287158A
(zh)
*
|
2021-12-08 |
2023-06-23 |
初源海生物科技(深圳)有限公司 |
一种新抗原鉴定和疗效预测方法
|
|
CN119072330A
(zh)
|
2022-03-14 |
2024-12-03 |
世代生物公司 |
异源初免加强疫苗组合物和使用方法
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
JP2025541604A
(ja)
|
2022-11-02 |
2025-12-22 |
ティゲン・ファーマ・ソシエテ・アノニム |
リンパ球の拡大
|
|
US12531162B1
(en)
*
|
2023-05-31 |
2026-01-20 |
Northeastern University |
Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
|
|
EP4474016A1
(en)
|
2023-06-07 |
2024-12-11 |
Julius-Maximilians-Universität Würzburg |
Strategies to target extracellularly accessible ras protein
|
|
WO2024261339A1
(en)
|
2023-06-23 |
2024-12-26 |
Tigen Pharma Sa |
Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
|
|
US12562256B2
(en)
*
|
2023-11-07 |
2026-02-24 |
New York University |
Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|